Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 1.00 |
| ▸ | CTSB | P07858 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Simeprevir SCHEMBL2229194 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18539068 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL6876363 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL829744 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL25465130 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL12445256 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL25465866 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18537915 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL18697017 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Simeprevir SCHEMBL1070885 | 1.00 | CTSS (1.00) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2045 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| CN-122028940-A | PI4K inhibitor and application thereof | 清华大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260103504-A1 | Chimeric Antigen Receptor Polypeptides and Methods of Using Same | UNIV LELAND STANFORD JUNIOR (US) | 2026-04-16 | — | — | US | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4719428-A1 | METHOD OF TREATING HEPATITIS C VIRUS IN PATIENTS | Altesa Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260078164-A1 | Regulatable Cell Surface Receptors and Related Compositions and Methods | UNIV LELAND STANFORD JUNIOR (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20220090040-A1 | Fusion Constructs for Controlling Protein Function | SENTI BIOSCIENCES, INC. (US) | 2022-03-24 | — | — | US | claimed |
| EP-3426250-B1 | TREATING A PATIENT WITH A CYP3A4 SUBSTRATE DRUG CONTRAINDICATED FOR CONCOMITANT ADMINISTRATION WITH A STRONG CYP3A4 INHIBITOR | Bow River LLC (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3969037-A2 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | Trustees of Boston University (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022047047-A1 | INHALABLE THERAPEUTIC AGENTS | CILA THERAPEUTIC INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220054495-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF ANTIVIRAL AGENTS | Poviva Corp. (US) | 2022-02-24 | — | — | US | claimed |
| EP-3952841-A1 | DRUG ADSORBED HIGHLY POROUS ACTIVATED CARBON FOR ENHANCED DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-3947432-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | Trustees of Boston University (US) | 2022-02-09 | — | — | EP | claimed |